Association of Body Composition with Outcome of Docetaxel Chemotherapy in Metastatic Prostate Cancer: A Retrospective Review

摘要: Background Docetaxel, a lipophilic drug, is indicated for castration-resistant metastatic prostate cancer. Most men with such disease would have had androgen-deprivation therapy, which decreases muscle and increases body fat. Obesity composition changes may influence the outcomes of docetaxel therapy. Methods We conducted retrospective review 333 patients cancer treated at comprehensive center between October 7, 2004 December 31, 2012. Body parameters were measured based on areas adipose tissues in visceral subcutaneous compartments CT images L3-4 levels. Dose calculations, toxicity adverse reaction profiles, overall survival analyzed. Results Obese younger diagnosis shorter duration from to therapy. Analysis found that high fat-to-subcutaneous fat area ratio (VSR) was associated poor prognosis but fat-to-muscle (VMR) mass index increased starting death, allowing catch up normal death. Cox proportional hazard regression showed age ≥65 years, VSR, abnormal serum alkaline phosphatase, >10% reduction initial dosage significant predictors time VMR, obesity, weekly regimens longer after docetaxel. Conclusion overweight benefit more using reference 35 mg/m2 without empirical reduction.